Overcoming Suppressive Tumor Microenvironment by Vaccines in Solid Tumor

被引：12

作者：

Xie, Ya-Jia ^{[1
]}

Liu, Wen-Qian ^{[1
]}

Li, Dan ^{[2
]}

Hou, Jin-Cai ^{[2
]}

Coghi, Paolo Saul ^{[1
]}

Fan, Xing-Xing ^{[1
]}

机构：

[1] Macau Univ Sci & Technol, State Key Lab Qual Res Chinese Med, Macau 999078, Peoples R China

[2] Beijing Wanteer Biol Pharmaceut Co Ltd, 32 yard,East 2nd Rd, Beijing 101400, Peoples R China

来源：

VACCINES | 2023年 / 11卷 / 02期

关键词：

cancer vaccines; immunosuppressive TME; solid tumor; immunotherapy; nanovaccines; ANTITUMOR IMMUNE-RESPONSES; MESSENGER-RNA VACCINES; LAHERPAREPVEC T-VEC; HUMAN-PAPILLOMAVIRUS; DENDRITIC CELLS; CERVICAL-CANCER; GLOBAL BURDEN; DNA; IMMUNOGENICITY; IMMUNOTHERAPY;

D O I：

10.3390/vaccines11020394

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Conventional vaccines are widely used to boost human natural ability to defend against foreign invaders, such as bacteria and viruses. Recently, therapeutic cancer vaccines attracted the most attention for anti-cancer therapy. According to the main components, it can be divided into five types: cell, DNA, RNA, peptide, and virus-based vaccines. They mainly perform through two rationales: (1) it trains the host immune system to protect itself and effectively eradicate cancer cells; (2) these vaccines expose the immune system to molecules associated with cancer that enable the immune system to recognize and destroy cancer cells. In this review, we thoroughly summarized the potential strategies and technologies for developing cancer vaccines, which may provide critical achievements for overcoming the suppressive tumor microenvironment through vaccines in solid tumors.

引用

页数：19

共 95 条

[1] Development of Peptide-Based Vaccines for Cancer [J].

Abd-Aziz, Noraini ;

Poh, Chit Laa .

JOURNAL OF ONCOLOGY, 2022, 2022

[2] Nanovaccines in cancer immunotherapy: Focusing on dendritic cell targeting [J].

Achmad, Harun ;

Ibrahim, Yousif Saleh ;

Al-Taee, Muataz Mohammed ;

Gabr, Gamal A. ;

Riaz, Muhammad Waheed ;

Alshahrani, Shadia Hamoud ;

Ramirez-Coronel, Andres Alexis ;

Jalil, Abduladheem Turki ;

Budi, Hendrik Setia ;

Sawitri, Windi ;

Stanislavovna, Malyutina Elena ;

Gupta, Jitendra .

INTERNATIONAL IMMUNOPHARMACOLOGY, 2022, 113

[3] Poly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs [J].

Ammi, Rachid ;

De Waele, Jorrit ;

Willemen, Yannick ;

Van Brussel, Ilse ;

Schrijvers, Dorien M. ;

Lion, Eva ;

Smits, Evelien L. J. .

PHARMACOLOGY & THERAPEUTICS, 2015, 146 :120-131

[4] Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma [J].

Andtbacka, Robert H. I. ;

Kaufman, Howard L. ;

Collichio, Frances ;

Amatruda, Thomas ;

Senzer, Neil ;

Chesney, Jason ;

Delman, Keith A. ;

Spitler, Lynn E. ;

Puzanov, Igor ;

Agarwala, Sanjiv S. ;

Milhem, Mohammed ;

Cranmer, Lee ;

Curti, Brendan ;

Lewis, Karl ;

Ross, Merrick ;

Guthrie, Troy ;

Linette, Gerald P. ;

Daniels, Gregory A. ;

Harrington, Kevin ;

Middleton, Mark R. ;

Miller, Wilson H., Jr. ;

Zager, Jonathan S. ;

Ye, Yining ;

Yao, Bin ;

Li, Ai ;

Doleman, Susan ;

VanderWalde, Ari ;

Gansert, Jennifer ;

Coffin, Robert S. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (25) :2780-U98

[5]

[Anonymous], MRNA 4157 CANC VACCI

[6] Dendritic Cells in Anticancer Vaccination: Rationale for Ex Vivo Loading or In Vivo Targeting [J].

Baldin, Alexey V. ;

Savvateeva, Lyudmila V. ;

Bazhin, Alexandr V. ;

Zamyatnin, Andrey A., Jr. .

CANCERS, 2020, 12 (03)

[7] The clinical progress of mRNA vaccines and immunotherapies [J].

Barbier, Ann J. ;

Jiang, Allen Yujie ;

Zhang, Peng ;

Wooster, Richard ;

Anderson, Daniel G. .

NATURE BIOTECHNOLOGY, 2022, 40 (06) :840-854

[8] mRNA-Based Cancer Vaccines: A Therapeutic Strategy for the Treatment of Melanoma Patients [J].

Bidram, Maryam ;

Zhao, Yue ;

Shebardina, Natalia G. ;

Baldin, Alexey V. ;

Bazhin, Alexandr V. ;

Ganjalikhany, Mohamad Reza ;

Zamyatnin, Andrey A. ;

Ganjalikhani-hakemi, Mazdak .

VACCINES, 2021, 9 (10)

[9] CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity [J].

Bijker, Martijn S. ;

van den Eeden, Susan J. F. ;

Franken, Kees L. ;

Melief, Cornelis J. M. ;

Offringa, Rienk ;

van der Burg, Sjoerd H. .

JOURNAL OF IMMUNOLOGY, 2007, 179 (08) :5033-5040

[10]

Bode C, 2011, EXPERT REV VACCINES, V10, P499, DOI [10.1586/ERV.10.174, 10.1586/erv.10.174]

← 1 2 3 4 5 6 7 8 9 10 →